Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041759 | 0.90 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL18425177 | 0.87 | HTR2C (0.44) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL6558562 | 0.81 | DDB1 (0.47) | CYP3A4CYP2D6SLC6A4GAA | |
| SCHEMBL6556640 | 0.81 | CYP3A4 (0.42) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL6557753 | 0.79 | DDB1 (0.51) | CYP3A4CYP2D6SLC6A4 | |
| SCHEMBL11844345 | 0.75 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL30440992 | 0.74 | DDB1 (0.41) | CYP3A4CYP2D6LMNA | |
| SCHEMBL3828096 | 0.74 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4129415 | 0.74 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL10814246 | 0.73 | DRD1 (0.54) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018175-B2 | 3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives | TAKEDA GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| EP-2813509-A1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | Takeda GmbH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2513119-B1 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-C]ISOQUINOLINE DERIVATIVES | TAKEDA GMBH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20120289474-A1 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-c] ISOQUINOLINE DERIVATIVES | NYCOMED GMBH (DE) | 2012-11-15 | — | — | US | disclosed |
| EP-2513119-A1 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c]ISOQUINOLINE DERIVATIVES | Nycomed GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073231-A1 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES | NYCOMED GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| EP-0988302-B1 | BENZONAPHTHYRIDINES | ALTANA PHARMA AG (DE) | 2003-02-19 | — | — | EP | disclosed |
| US-6384047-B1 | BREATHING DISORDERS AND HYPOTENSIVE AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289474-A1 | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-c] ISOQUINOLINE DERIVATIVES | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.